| # | Filing Date | Period End Date | Type | Report Link | 
|---|---|---|---|---|
| 1 | 08-12-2025 | 06-30-2025 | 10-Q | |
| 2 | 05-15-2025 | 03-31-2025 | 10-Q | |
| 3 | 03-11-2025 | 12-31-2024 | 10-K | |
| 4 | 11-12-2024 | 09-30-2024 | 10-Q | 
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	Citigroup analyst Yigal Nochomovitz maintains Zenas BioPharma (NASDAQ:ZBIO) with a Buy and raises the price target from $27 ...
 
																	Morgan Stanley analyst Vikram Purohit maintains Zenas BioPharma (NASDAQ:ZBIO) with a Overweight and raises the price target ...
 
																	HC Wainwright & Co. analyst Matthew Caufield maintains Zenas BioPharma (NASDAQ:ZBIO) with a Buy and raises the price tar...
 
																	
 
																	
 
																	 
																	- SEC Filing
 
																	Wedbush analyst Martin Fan maintains Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and raises the price target from $35 t...
 
																	HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $30 price...